Cioteronel
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral, topical |
| ATC code | None |
| Identifiers | |
| |
| CAS Number | 89672-11-7 |
| PubChem (CID) | 55994 |
| ChemSpider | 50555 |
| UNII | 1RTH95874Z |
| ChEMBL | CHEMBL2104105 |
| Chemical and physical data | |
| Formula | C16H28O2 |
| Molar mass | 252.39232 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Cioteronel (INN, USAN) (developmental code name CPC-10997; former tentative brand names Cyoctol, Ethocyn, X-Andron) is a non-steroidal antiandrogen that was never marketed.[1][2][3] It was under development over the course of 1989 to 2001 for the topical treatment of androgenetic alopecia (male pattern baldness) and acne and for the oral treatment of benign prostatic hyperplasia; it reached phase III clinical trials for acne and phase II studies for androgenetic alopecia, but was ultimately discontinued due to poor efficacy.[3][4]
See also
References
- ↑ C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 570–. ISBN 978-0-412-46630-4.
- ↑ Daniel Lednicer (21 November 1994). The Organic Chemistry of Drug Synthesis. John Wiley & Sons. pp. 11–. ISBN 978-0-471-58959-4.
- 1 2 Tiwari, Atul; Krishna, N S; Nanda, Kamna; Chugh, Anita (2005). "Benign prostatic hyperplasia: an insight into current investigational medical therapies". Expert Opinion on Investigational Drugs. 14 (11): 1359–1372. doi:10.1517/13543784.14.11.1359. ISSN 1354-3784.
- ↑ https://adisinsight.springer.com/drugs/800003205[]
This article is issued from Wikipedia - version of the 11/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.